Logo Logo
Switch Language to German

Klimek, L.; Förster-Ruhrmann, U.; Olze, H.; Beule, A. G.; Chaker, A. M.; Hagemann, J.; Huppertz, T.; Hoffmann, T. K.; Dazert, S.; Deitmer, T.; Strieth, S.; Wrede, H.; Schlenter, W.; Welkoborsky, H. J.; Wollenberg, B.; Becker, S.; Klimek, F.; Sperl, A.; Casper, I.; Zuberbier, J.; Rudack, C.; Cuevas, M.; Hintschich, C. A.; Guntinas-Lichius, O.; Stoever, T.; Bergmann, C.; Pfaar, O.; Gosepath, J.; Groeger, M.; Beutner, C.; Laudien, M.; Weber, R. K.; Hildenbrand, T.; Hoffmann, A. S. and Bachert, C. (2022): Empfehlungen zur Überprüfung der Wirksamkeit und Verlaufsdokumentation von Dupilumab bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP) im deutschen Gesundheitssystem. In: Laryngo-Rhino-Otologie, Vol. 101, No. 11: pp. 855-865

Full text not available from 'Open Access LMU'.


Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the nasal and paranasal mucosa. A Type-2 inflammation is described as the most common endotype. Since October 2019 the anti-IL-4/-IL-13 antibody dupilumab has been approved in Germany as an add-on therapy to intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps, when systemic corticosteroids alone or surgery do not provide adequate disease control. While recommendations for the use of dupilumab in CRSwNP exist at both national and international levels, until now it has not been adequately established, how therapy should be monitored and when it should be discontinued in the German Health Care System. Methods A literature search was performed analyzing previous data on the treatment of CRSwNP with dupilumab and to determine the available evidence by searching Medline, Pubmed, the national and international trial and guideline registries and the Cochrane Library. Human studies published in the period up to 05/2022 were included. Results Based on international literature and previous experience, recommendations are given by an expert panel for follow-up and possible therapy breaks, therapy intervals or termination of therapy when using dupilumab for the indication CRSwNP in the German health care system based on a documentation form. Conclusions Understanding the immunological basis of CRSwNP opens new non-surgical therapy approaches with biologics for patients with severe courses. The authors give recommendations for follow-up, possible therapy breaks, therapy intervals and a termination for dupilumab treatment as add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP that cannot be adequately controlled with systemic corticosteroids and/or surgical intervention.

Actions (login required)

View Item View Item